Share This Page
Drugs in ATC Class A10BJ
✉ Email this page to a colleague
Drugs in ATC Class: A10BJ - Glucagon-like peptide-1 (GLP-1) analogues
| Tradename | Generic Name |
|---|---|
| BYDUREON | exenatide synthetic |
| BYDUREON PEN | exenatide synthetic |
| BYETTA | exenatide synthetic |
| EXENATIDE SYNTHETIC | exenatide synthetic |
| BYDUREON BCISE | exenatide synthetic |
| LIRAGLUTIDE | liraglutide |
| SAXENDA | liraglutide |
| >Tradename | >Generic Name |
Market dynamics and patent landscape for ATC Class A10BJ (GLP‑1 analogues): What patents protect, when exclusivity ends, and where generics/biosimilars face barriers
ATC Class A10BJ covers glucagon-like peptide‑1 (GLP‑1) analogues. The market is led by products with multi-layer IP: (1) long-acting molecule and primary composition patents, (2) device and formulation/controlled-release patents, (3) second medical-use patents, and (4) process and manufacturing patents. Near-term competitive risk concentrates where Orange Book listings show “waiting” periods beyond the first drug approval, and where new entrants target specific salts/strengths/delivery systems. In practice, launch timing is more constrained by formulation and device-linked patents than by early method-of-use claims.
Which GLP‑1 analogues are in ATC A10BJ and how does the market segment across daily vs once-weekly?
What products define competitive dynamics in A10BJ?
GLP‑1 analogue brands and typical positioning in A10BJ markets include:
- Once-daily GLP‑1 analogues (historically including liraglutide-class products)
- Once-weekly GLP‑1 analogues (long-acting delivery systems)
How do dosing cadence and administration drive IP strategy?
Long-acting GLP‑1s concentrate patent protection into:
- Formulation (solubilizers, stabilizers, particle size or microstructure, viscosity targets)
- Controlled release (depot matrices such as polymeric systems)
- Needle/device architecture (injector springs, pen compatibility, delivery accuracy)
This shifts enforcement from “molecule-only” claims to a combination of product-by-process and device-by-injection.
What patents protect GLP‑1 analogues across the value chain (molecule, formulation, device, and use)?
Molecule and composition of matter
Core protection typically includes:
- Novel GLP‑1 analogue sequences/analogs
- Pharmaceutical compositions containing the analogue
- Salt/hydrate forms where claimed
Commercial implication: generic manufacturers must design around specific analog structures and claimed compositions, not only “GLP‑1 as a class.”
Formulation and controlled-release system patents
Long-acting GLP‑1s often depend on:
- Depot formulation composition targets
- Stabilization chemistry for storage life and freeze-thaw resistance
- Particle/microstructure parameters that maintain release kinetics
Commercial implication: a generic can sometimes match therapeutic exposure while still infringing formulation release-profile claims.
Injection device and method-of-administration patents
Where relevant, device-linked patents cover:
- Pen compatibility features
- Dosage setting and mechanical delivery steps
- Needle geometry tied to delivery performance
Commercial implication: a Section 505(b)(2) or ANDA pathway can still trigger infringement if the applicant uses a claimed injection method or device architecture.
Method-of-use patents (Type 2 diabetes, weight management, cardiovascular outcomes)
Method-of-use coverage tends to cover:
- Specific patient populations
- Specific dosing regimens
- Endpoints such as CV risk reduction claims
Commercial implication: even after molecule/formulation patent expiration, method-of-use patents can delay marketing for new label indications.
How many patents cover GLP‑1 analogues and what claim clusters drive litigation outcomes?
Patent estate structure across major GLP‑1 platforms
The most litigated estate components are usually:
- Composition/formulation patents (controlled release, depot composition)
- Manufacturing/process patents (sterile fill process, mixing/particle formation)
- Device/administration method patents (where claimed)
- Key method-of-use patents tied to specific label expansions
Litigation tends to concentrate where?
Courts and settlements typically focus on patents that are:
- Asserted as necessary for infringement due to dosage form match
- Directly implicated by the defendant’s proposed formulation and manufacturing approach
- Linked to pivotal “blocker” periods that constrain at-risk launch
When does exclusivity end for GLP‑1 analogues in ATC A10BJ, and what drives the delay beyond “first filing”?
What ends first: regulatory exclusivity vs patent expiration?
For injectable GLP‑1 analogues, market entry constraints commonly stack:
- Regulatory exclusivity (data exclusivity periods and orphan-related, when applicable)
- Patent expiration (composition, formulation, and method-of-use)
- PTE/PB extensions that move the effective patent expiry date
Operational implication: launch calendars usually depend on the latest-expiring “blocking” patent family, not the earliest composition expiry.
What typically extends the window after initial approval?
Two patterns dominate:
- Additional marketing authorizations (label expansions) tied to additional method-of-use patents
- New dosage strengths and delivery systems supported by formulation and device patents
Which Orange Book status and FDA listings typically block generic entry for A10BJ GLP‑1 analogues?
What to check on Orange Book (high-signal fields)?
High-intent checks for generic risk:
- Listed patents with the relevant drug product (specific strength and dosage form)
- Patent type classifications (composition vs method of use vs formulation)
- Patent expiration dates (including extensions where shown)
- Patent status codes tied to exclusivity
How “waiting” can occur after primary expiry
Even when a first patent family expires, generics can face:
- Remaining formulation patents for long-acting depots
- Remaining method-of-use patents for expanded labels
- Patent thickets for multiple strengths
How do Paragraph IV challenges reshape GLP‑1 competition and settlement timing?
What Paragraph IV strategy looks like for long-acting GLP‑1s?
Applicants typically attempt to launch by asserting non-infringement or invalidity for:
- The most directly asserted formulation patents
- Process patents tied to the depot formation
- Method-of-use patents for specific indications where label carve-outs are possible
Settlement patterns that affect market dynamics
Settlements in this class typically:
- Set a defined launch date for the generic, often tied to a later-expiring patent
- Include territory and sometimes skinny labeling restrictions
- Include agreement clauses on ongoing disputes related to formulation/device modifications
What patent litigation affects GLP‑1 analogues most (and what claims are most commonly targeted)?
High-frequency infringement targets
Litigation most often asserts:
- Formulation/control-release patents that match the defendant’s depot design
- Composition patents for the analogue entity
- Method-of-use patents tied to label claims
Manufacturing/process patents: why they matter in practice
Even when formulations are “similar,” process patents can:
- Determine whether a manufacturing step meets a claimed parameter
- Trigger infringement if the process falls inside a claimed range
How does the patent estate for once-weekly GLP‑1s compare with once-daily GLP‑1s?
Are once-weekly products more IP-dense?
Long-acting products typically have:
- Higher number of formulation and controlled-release patents
- More device and manufacturing process patents due to depot complexity
What does this mean for biosimilar/generic timelines?
Once-weekly entries face:
- More “blocking” formulation claims
- More settlement leverage around depot and injection compatibility
Biosimilar risk: Does ATC A10BJ include biosimilars, and where do biologic-like constraints appear?
Can a GLP‑1 analogue be treated as a biosimilar?
In general practice:
- Most GLP‑1 analogues are treated as small-molecule-like injectables for generic development (depending on jurisdiction and regulatory framework)
- True biosimilar pathways apply when the product is considered biologic under the relevant system
In biosimilar-like settings, the IP barriers usually include:
- Manufacturing comparability patents (process controls)
- Formulation stability and delivery patents
- Method-of-use patents tied to clinical endpoints
What formulations are protected by patents for GLP‑1 depot injectables?
Controlled-release formulation claim themes
Claim themes commonly include:
- Depot polymer or matrix compositions
- Surfactant and stabilizer systems
- Viscosity and release rate target ranges
- Storage and reconstitution conditions (when relevant)
What generic entrants must avoid
To reduce infringement risk, entrants often try to:
- Modify depot matrix composition
- Alter particle size/microstructure formation steps
- Change mixing or sterilization steps tied to process claims
- Use alternative injection delivery mechanics if device patents are asserted
What method-of-use patents protect GLP‑1 indications, and what label carve-outs do generics pursue?
Typical method-of-use claim targets
Method-of-use patents often cover:
- Cardiovascular outcomes populations
- Weight management indications
- Specific dosing regimens and titration schedules
How label design affects infringement exposure
Applicants seeking market entry often pursue:
- “Carve-out” labeling that avoids the method-of-use claim scope
- Timing strategy that launches only after the relevant method-of-use patent expiry for the targeted indication
Which companies control the GLP‑1 analogue patent landscape and where are the repeat players in litigation?
Pattern of competitive control
Across A10BJ, the pattern is that:
- Originators hold the core analogue and formulation patents
- Generic/biosimilar challengers become repeat players in Paragraph IV disputes tied to these families
What this implies for licensing leverage
Originators typically leverage:
- Settlement windows tied to the latest “blocking” formulation patent
- Cross-licensing around process and device improvements for subsequent generations
How do manufacturing and IP barriers affect “at-risk” launches of GLP‑1 analogues?
What barriers dominate
- Controlled-release formulation patents
- Process and particle/matrix formation patents
- Device injection method compatibility patents
- End-point/indication method-of-use patents
What “design around” usually means
Successful design-around in this class typically requires:
- Meaningful changes to depot formulation or process steps
- Changes that avoid literal infringement, and in some cases avoid doctrine-of-equivalents risk by changing the “way it works” characteristics for release.
Key timeline framework: how to map exclusivity end dates to market entry risk in A10BJ
Practical timeline view used in launch planning
- Regulatory exclusivity window ends (data exclusivity and any additional exclusivity where applicable)
- Earliest patent expiry on molecule/composition
- Next blocking patent expiry for formulation/device
- Method-of-use patent expiry aligned to the specific indication
- Final at-risk launch window after all blockers for the intended label
What “latest blocker” typically determines
For long-acting GLP‑1 injectables, the final blocker is often:
- A formulation/depot patent family or a combination of formulation plus device/administration patents
- Followed by method-of-use patents that cover the commercial label
Key Takeaways
- ATC A10BJ GLP‑1 analogue competition is driven by stacked IP: molecule plus formulation/control-release, plus manufacturing/process and sometimes device-linked claims.
- Launch timing is governed less by earliest molecule expiry and more by the latest blocking formulation/device and method-of-use patents.
- Generic and challenge strategies focus on specific strengths/dosage forms and label carve-outs, reducing infringement exposure while preserving commercial entry windows.
- In this class, the highest litigation leverage typically sits in depot formulation and process claims, with settlements often pegged to a later-expiring blocking family rather than the first composition expiry.
FAQs
1) What patents protect depot formulations for GLP‑1 analogues?
Depot formulation patents typically cover controlled-release matrix compositions, stabilizers, viscosity and release-rate parameters, and storage-stability requirements tied to the long-acting injectable.
2) When does a GLP‑1 generic face the biggest risk, composition or formulation?
For long-acting GLP‑1 analogues, formulation and controlled-release depot patents usually create the highest risk, especially when device delivery and manufacturing process claims are asserted.
3) How do Orange Book listings signal whether a generic launch is feasible?
Orange Book listings show the specific drug product and relevant patent types; feasibility depends on whether the applicant can avoid infringement for all blocking patents covering the intended strength/dosage form and label.
4) Do method-of-use patents delay competition after molecule expiry?
Yes. Even after composition/formulation expiry, method-of-use patents tied to specific indications can delay marketing unless applicants use label carve-outs that avoid claim scope.
5) What does an effective Paragraph IV strategy look like for ATC A10BJ GLP‑1s?
A strategy usually targets the most directly asserted formulation/device or process patents for the relevant dosage form, while aligning label design to avoid method-of-use claims for the targeted indication.
References
- U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed 2026).
- U.S. Food and Drug Administration. Drug Approval and Databases (Drugs@FDA). (Accessed 2026).
More… ↓
